The Centers for Medicare and Medicaid Services could authorize lower-cost generic versions of Astellas Pharma and Pfizer’s prostate cancer drug Xtandi in government-sponsored insurance programs using existing federal government licensing and patent rights that are separate from march-in rights, a trio of advocacy organizations argued in a 9 April letter.
Key Takeaways
-
Now that a march-in request for Xtandi has failed again, advocates are pushing alternatives that could accelerate the launch of generic enzalutamide in federal programs.
The request by Knowledge Ecology International, Universities Allied for Essential Medicines and the Union for Affordable Cancer Treatment is the...
